[{"id":"51666f07-e257-46bc-8e85-ae4fa60ad285","acronym":"","url":"https://clinicaltrials.gov/study/NCT05137275","created_at":"2021-11-30T12:53:36.156Z","updated_at":"2024-07-02T16:36:01.750Z","phase":"Phase 1","brief_title":"Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05137275","lead_sponsor":"Shanghai East Hospital","biomarkers":" HER-2 • ER • ALK • PGR • IL6 • CD4 • IL2 • NCAM1 • IL10","pipe":" | ","alterations":" EGFR mutation","tags":["HER-2 • ER • ALK • PGR • IL6 • CD4 • IL2 • NCAM1 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IBR854"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 11/24/2021","start_date":" 11/24/2021","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2022-10-27"},{"id":"2b0b5896-5765-4d6e-ae97-036a396815eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05194709","created_at":"2022-01-18T12:54:11.251Z","updated_at":"2024-07-02T16:36:17.717Z","phase":"Phase 1","brief_title":"Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors","source_id_and_acronym":"NCT05194709","lead_sponsor":"Wuxi People's Hospital","biomarkers":" IFNG • IL6 • CD4 • IL2 • NCAM1 • IL10 • IL1B • CRP","pipe":"","alterations":" ","tags":["IFNG • IL6 • CD4 • IL2 • NCAM1 • IL10 • IL1B • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anti-5T4 CAR-NK Cell Therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/30/2021","start_date":" 12/30/2021","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2022-02-02"}]